Aurobindo Pharma Limited announced its consolidated financial results for the quarter ended December 31, 2024. Revenue from Operations increased by 8.5% YoY to Rs. 7,979 crore with growth across the businesses. Net profit for the period stood at Rs. 846 crore.  

During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore. Europe formulations revenue increased by 22.7% YoY to Rs. 2,121 crore. Growth Markets revenue increased by 39.3% YoY to Rs. 873 crore. The company received final approval for 8 ANDAs (including 1 ANDA previously tentatively approved, now received the final approval) from the USFDA

Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the company said: “We are pleased to report our highest-ever quarterly revenue, driven by volume growth from our diverse and expanding product portfolio coupled with new launches. This performance highlights our resilience. Looking ahead, we are enhancing our manufacturing capabilities and ramping up our specialty and injectable business. With these initiatives, we expect notable profitability improvements and are well-positioned to sustain growth and meet our objectives for the year."